@article{647b956a31f445cea5ab7addf4e05022,
title = "A 51-Year-Old Woman With Interstitial Lung Disease and Subsequent COVID-19 Presenting With Worsening Dyspnea",
abstract = "Case Presentation: A 51-year-old Puerto Rican woman, with a known but inconclusive diagnosis of interstitial lung disease (ILD) since 2002 and recent moderate COVID-19, is now presenting with subacute worsening dyspnea on exertion. The patient had sporadic medical care over the years for her ILD (Table 1). Prior workup included chest CT imaging with a “crazy-paving” pattern of lung disease, as defined by ground-glass opacity with superimposed interlobular septal thickening and visible intralobular lines. Bronchoscopy showed normal airway examination, and BAL revealed clear fluid with foamy macrophages and negative cultures. Video-assisted thoracoscopic surgery and transbronchial biopsy specimens both showed foamy macrophages. Results of pulmonary function testing (PFT) revealed an isolated gas transfer defect on diffusing capacity of the lungs for carbon monoxide (DLCO). She had lived with mild yet nonprogressive functional impairment and stable exercise intolerance over these years. She was then hospitalized for COVID-19 in August 2020 and for recurrent shortness of breath in September 2020. She now presented 4 months following her September 2020 hospitalization.",
author = "Nicole Ng and Jigna Zatakia and Beasley, {Mary B.} and Michael Chung and Manisha Balwani and Chanan Stauffer and Schuchman, {Edward H.} and Sakshi Dua",
note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. B. is a coinvestigator receiving financial compensation as an advisory board member and lecturer for Genzyme Corporation (the study sponsor and manufacturer of olipudase alfa which is described in the manuscript). E. H. S. is one of the inventors on patents owned by the Mount Sinai School of Medicine and licensed to Genzyme for the development of enzyme replacement therapy for the treatment of Niemann-Pick disease; he also is a consultant for Genzyme regarding this disease and a member of Genzyme's Speakers Bureau. The Department of Genetics and Genomics Sciences along with some faculty members in the department receive royalty payments from Genzyme for the development of drug therapy for genetic diseases other than sphingomyelinase, the focus of the current manuscript. In addition, the Department of Genetics and Genomic Sciences receive support for maintaining the Gaucher Registry, which is sponsored by Genzyme. None declared (N. N. J. Z. M. B. B. M. C. C. S. S. D.). Other contributions: CHEST worked with the authors to ensure that the Journal policies on patient consent to report information were met. Publisher Copyright: {\textcopyright} 2022 American College of Chest Physicians",
year = "2022",
month = jul,
doi = "10.1016/j.chest.2022.01.059",
language = "English",
volume = "162",
pages = "e19--e25",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",
}